A synthetic peptide for use as a blocking control in assays to test for specificity of NDP antibody, Alternative Names: NDP control peptide, NDP antibody Blocking Peptide, Anti-NDP Blocking Peptide, Norrie Disease Blocking Peptide, Pseudoglioma Blocking Peptide, EVR2 Blocking Peptide, FEVR Blocking Peptide, ND Blocking Peptide
Aufreinigung
Rabbit Anti-p44/42 MAP Kinase (Ab-202) Polyclonal Antibody is affinity-purified from rabbit antiserum by affinity chromatography using epitope-specific immunogen.
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
Norrie Disease (Pseudoglioma) (NDP)
Hintergrund
NDP activates the canonical Wnt signaling pathway through FZD4 and LRP5 coreceptor. NDP plays a central role in retinal vascularization by acting as a ligand for FZD4 that signals via stabilizing beta-catenin (CTNNB1) and activating LEF/TCF-mediated transcriptional programs. NDP acts in concert with TSPAN12 to activate FZD4 independently of the Wnt-dependent activation of FZD4, suggesting the existence of a Wnt-independent signaling that also promote accumulation the beta-catenin (CTNNB1).